NeuroThera effectiveness and safety trial 3: How do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?

Steven R. Levine; Michael D. Hill

doi:10.1161/STROKEAHA.114.006750

NeuroThera effectiveness and safety trial 3: How do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?

Steven R. Levine
, Michael D. Hill

Neurology

SUNY Downstate Health Sciences University

University of Calgary

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	3175-3177
Number of pages	3
Journal	Stroke
Volume	45
Issue number	11
DOIs	https://doi.org/10.1161/STROKEAHA.114.006750
State	Published - 2014

Keywords

Clinical trials phase III
Ethics
Scientific integrity review

Access to Document

10.1161/STROKEAHA.114.006750

Cite this

@article{189b8cf81d524c02be0e9bd7a130f3b5,

title = "NeuroThera effectiveness and safety trial 3: How do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?",

keywords = "Clinical trials phase III, Ethics, Scientific integrity review",

author = "Levine, \{Steven R.\} and Hill, \{Michael D.\}",

year = "2014",

doi = "10.1161/STROKEAHA.114.006750",

language = "English",

volume = "45",

pages = "3175--3177",

journal = "Stroke",

issn = "0039-2499",

number = "11",

}

TY - JOUR

T1 - NeuroThera effectiveness and safety trial 3

T2 - How do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?

AU - Levine, Steven R.

AU - Hill, Michael D.

PY - 2014

Y1 - 2014

KW - Clinical trials phase III

KW - Ethics

KW - Scientific integrity review

UR - https://www.scopus.com/pages/publications/84922482237

U2 - 10.1161/STROKEAHA.114.006750

DO - 10.1161/STROKEAHA.114.006750

M3 - Review article

C2 - 25293661

SN - 0039-2499

VL - 45

SP - 3175

EP - 3177

JO - Stroke

JF - Stroke

IS - 11

ER -

NeuroThera effectiveness and safety trial 3: How do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly?

Keywords

Access to Document

Other files and links

Fingerprint

Cite this